Genvor Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization

Rhea-AI Summary

Genvor (OTCQB: GNVR) appointed Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. Dr. Stavrides brings 15+ years in agrochemical and biological product management, including roles at Syngenta where he oversaw >50 global product launches and helped quadruple revenues over seven years.

He will lead commercial strategy, partnerships, licensing and collaboration efforts to advance Genvor’s AI-accelerated peptide platform and expand market access to growers worldwide.

Positive

• Experienced hire: Dr. George Stavrides brings 15+ years in agrochemical and biological commercialization
• Proven commercial record: Oversaw over 50 global product launches and helped quadruple revenues over seven years
• Partnership focus: Role explicitly targets expansion of strategic partnerships, licensing, and collaborations

Negative

• None.

Agricultural biologicals leader brings 15+ years of global R&D and product management experience from Syngenta to accelerate Genvor’s strategic partnerships and market expansion

Woodland, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies.

Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years.

“George’s track record of building successful commercial partnerships and bringing biological technologies to market at a global scale makes him the ideal leader to accelerate Genvor’s commercialization efforts,” said Chad Pawlak, Chief Executive Officer of Genvor. “His deep expertise in evaluating and executing strategic collaborations combined with his hands-on experience scaling biocontrol portfolios will be instrumental as we advance discussions with major agricultural companies and bring our peptide-based solutions to growers worldwide.”

“Every time a future biologicals technology such as peptides shapes an innovation into a product concept, the industry gets a step closer in addressing unmet grower needs,” said Dr. Stavrides. “In this highly complex process, a mesh of clearly set strategic considerations across regulatory, development, marketing and commercialization needs to be properly laid out. This is where I will be concentrating my efforts supporting the Genvor team to help the company realize the peptide technology platform’s potential and exceed their strategic ambition. I am excited to be part of the team.”

Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD.

About Genvor

Genvor, Inc. (OTCQB: GNVR) is a biotechnology company pioneering peptide-based solutions for crop protection and plant health. With a focus on sustainable agriculture, Genvor develops and commercializes biological actives that enhance crop performance, reduce chemical inputs, and support regenerative farming systems. Through its partnerships and technology platforms, Genvor is advancing a new era of natural, science-based crop protection. For more information, visit www.genvor.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations and projections about future events and are not guarantees of future performance. Forward-looking statements include, among others, statements regarding the potential benefits and anticipated contributions of new executive appointments, strategic partnerships, and commercialization activities. Actual results may differ materially from those expressed or implied. Factors that could cause such differences include, but are not limited to, market conditions, competitive factors, regulatory developments, and the ability to execute on strategic initiatives. Genvor undertakes no obligation to update or revise forward-looking statements, except as required by law.

Contacts:

Genvor, Inc.
Investor Relations & Media
Carly Scaduto
carly@carlyscadutoconsulting.com

FAQ

Who is Genvor (GNVR) appointing as EVP of Business Development & Commercialization?

Genvor appointed Dr. George Stavrides as EVP, Business Development & Commercialization effective February 2, 2026. According to the company, he brings over 15 years of product management, regulatory and commercial leadership in agrochemicals and biologicals, most recently at Syngenta.

What experience does Dr. George Stavrides bring to Genvor (GNVR)?

Dr. Stavrides brings more than 15 years of industry experience, including global product management at Syngenta. According to the company, he led evaluation of 500+ biological concepts, managed a dozen collaborations, and oversaw over 50 product launches globally.

What will Dr. Stavrides’ responsibilities be at Genvor (GNVR)?

He will lead commercial strategy, partnerships, licensing and collaboration efforts to commercialize peptide technologies. According to the company, the role focuses on scaling strategic partnerships and accelerating market expansion to growers worldwide.

When does Dr. Stavrides start at Genvor (GNVR) and what is the effective date?

Dr. George Stavrides’ start date is February 2, 2026, as announced by the company. According to the company, he will immediately lead commercialization initiatives and partnership discussions with major agricultural firms.

How might Dr. Stavrides’ Syngenta background affect Genvor’s commercialization (GNVR)?

His Syngenta experience includes managing global product launches and partnership evaluations, which could strengthen commercialization execution. According to the company, his track record in scaling biocontrol portfolios is expected to support Genvor’s peptide platform rollout.